Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

1.

Breaking a vicious cycle.

Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR.

Sci Transl Med. 2013 Jul 31;5(196):196cm6. doi: 10.1126/scitranslmed.3005950.

2.

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Altman DG, McShane LM, Sauerbrei W, Taube SE.

PLoS Med. 2012;9(5):e1001216. doi: 10.1371/journal.pmed.1001216. Epub 2012 May 29.

3.

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Altman DG, McShane LM, Sauerbrei W, Taube SE.

BMC Med. 2012 May 29;10:51. doi: 10.1186/1741-7015-10-51.

4.

Challenges in drug and biomarker co-development.

Taube SE, Lively T.

Recent Results Cancer Res. 2012;195:229-39. doi: 10.1007/978-3-642-28160-0_21. Review.

PMID:
22527510
5.

Biomarkers in oncology: trials and tribulations.

Taube SE.

Ann N Y Acad Sci. 2009 Oct;1180:111-8. doi: 10.1111/j.1749-6632.2009.05019.x.

PMID:
19906265
6.

A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.

Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI.

J Natl Cancer Inst. 2009 Nov 4;101(21):1453-63. doi: 10.1093/jnci/djp334. Epub 2009 Oct 23.

7.

A system for sharing routine surgical pathology specimens across institutions: the Shared Pathology Informatics Network.

Drake TA, Braun J, Marchevsky A, Kohane IS, Fletcher C, Chueh H, Beckwith B, Berkowicz D, Kuo F, Zeng QT, Balis U, Holzbach A, McMurry A, Gee CE, McDonald CJ, Schadow G, Davis M, Hattab EM, Blevins L, Hook J, Becich M, Crowley RS, Taube SE, Berman J; Shared Pathology Informatics Network.

Hum Pathol. 2007 Aug;38(8):1212-25. Epub 2007 May 8.

PMID:
17490722
8.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology/College of American Pathologists.

Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2.

PMID:
19548375
9.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.

10.

REporting recommendations for tumor MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics.

Breast Cancer Res Treat. 2006 Nov;100(2):229-35. Epub 2006 Aug 24.

PMID:
16932852
11.

Reporting recommendations for tumor marker prognostic studies (remark).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Exp Oncol. 2006 Jun;28(2):99-105.

PMID:
16837898
12.

REporting recommendations for tumor MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Nat Clin Pract Urol. 2005 Aug;2(8):416-22.

PMID:
16482653
13.

Cancer diagnostics: decision criteria for marker utilization in the clinic.

Taube SE, Jacobson JW, Lively TG.

Am J Pharmacogenomics. 2005;5(6):357-64. Review.

PMID:
16336001
14.

Reporting recommendations for tumor marker prognostic studies.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

J Clin Oncol. 2005 Dec 20;23(36):9067-72. Epub 2005 Sep 19. No abstract available.

15.

REporting recommendations for tumor MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Nat Clin Pract Oncol. 2005 Aug;2(8):416-22.

PMID:
16130938
16.

REporting recommendations for tumour MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Br J Cancer. 2005 Aug 22;93(4):387-91.

17.

Reporting recommendations for tumor marker prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4.

18.

REporting recommendations for tumour MARKer prognostic studies (REMARK).

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics.

Eur J Cancer. 2005 Aug;41(12):1690-6.

PMID:
16043346
19.

Program for the Assessment of Clinical Cancer Tests (PACCT): implementing promising assays into clinical practice.

Jessup JM, Lively TG, Taube SE.

Expert Rev Mol Diagn. 2005 May;5(3):271-3. No abstract available.

PMID:
15934805
20.

Prognostic and predictive markers in cancer.

Conley BA, Taube SE.

Dis Markers. 2004;20(2):35-43. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk